ONGC: The state-owned oil & exploration company's consolidated net profit tumbled 52.73% to Rs 5,701.46 crore despite of 5.21% rise in revenue to Rs 164,066.72 crore in Q4 FY23 over Q4 FY22.
Aurobindo Pharma: The company's consolidated net profit fell 12.2% to Rs 505.9 crore in Q4 FY23 as against Rs 576.1 crore recorded in Q4 FY22. Revenue from operations stood at Rs 6473 crore in Q4 FY23, up 11.4% from Rs 5809.4 crore posted in Q4 FY22.
BEML: On standalone basis, BEML's net profit rose 17.6% to Rs 158.22 crore in Q4 FY23 as against Rs 134.50 crore posted in Q4 FY22. Revenue from operations declined 17.6% to Rs 1,387.94 crore in the quarter ended 31 March 2023.
BHEL: Bharat Heavy Electricals' (BHEL) consolidated net profit declined 33% to Rs 611 crore in Q4 FY23 as against Rs 912.47 crore reported in Q4 FY22. Revenue from operations rose 2.9% year on year (YoY) to Rs 7,819.37 crore in the quarter ended 31 March 2023.
Indigo Paints: Indigo Paints reported 40.7% jump in net profit to Rs 48.68 crore on 12.9% increase in revenue from operations to Rs 325.47 crore in Q4 FY23 over Q4 FY22.
City Union Bank: The private sector bank's net profit rose 4.3% to Rs 218.04 crore on 13.6% increase in total income to Rs 1,423.09 crore in Q4 FY23 over Q4 FY22.
Karnataka Bank: The private lender's net profit surged 171.4% to Rs 353.75 crore in Q4 FY23 as against Rs 130.35 crore recorded in Q4 FY22. Total income jumped 28.8% to Rs 2,364.54 crore in the quarter ended 31 March 2023.
Chambal Fertilisers & Chemicals: The company's consolidated net profit tumbled 61.4% to Rs 94.10 crore in Q4 FY23 as against Rs 243.57 crore recorded in Q4 FY22. Revenue from operations stood at Rs 3,598.67 crore in Q4 FY23, up 8.8% from Rs 3,307.37crore posted in Q4 FY22.
Sun Pharmaceutical Industries: The company has issued a letter to the Board of Directors of Taro Pharmaceutical Industries Ltd., Israel (Taro) with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares in Taro, other than any shares already held by the company or its affiliates (For a purchase price of $38 per ordinary share, in cash).
Lupin: The pharma major announced that its Canada subsidiary, Lupin Pharma Canada Ltd., has received approval from Health Canada to market a generic version of Spiriva (tiotropium bromide inhalation powder) for the treatment of chronic obstructive pulmonary disease (COPD), in Canada.
Powered by Capital Market - Live News